Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic acid-based biotherapeutic development, announced today that its partner, Colorcon, a world leader in the development and supply of film coating systems and excipients, formally launched the On-Dose Authentication capability to provide track and trace functionality for supply chain security. The seamless integration of molecular taggants from Applied DNA Sciences (ADNAS) into an Opadry® fully formulated film coating system significantly reduces the risks associated with counterfeit and falsified medications entering the supply chain.
This first commercial offering is the culmination of extensive collaboration between Colorcon and ADNAS to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form itself. By better understanding the vulnerabilities of a complex global supply chain, drug manufacturers can make informed decisions regarding distribution networks and deploy preventative measures to address counterfeiting and product diversion issues.
Dr. Ali Rajabi-Siahboomi, Vice President/Chief Scientific Officer at Colorcon Inc. says, “With new guidelines from regulators and accessible technology, on-dose solutions provide a more robust and reliable means of identifying and deterring counterfeiting, verifying product authenticity, and ensuring product traceability. Through extensive research and development, Colorcon has created a unique coating system to address this global problem.”
Kelly Boyer, General Manager, Film Coatings at Colorcon Inc. explains, “On-dose authentication technology represents the next generation in pharmaceutical supply-chain security by providing a powerful tool for tracking product from plant to patient. By seamlessly enabling authentication, these digitized coatings confirm the quality and origin of medicines thereby safeguarding both patients and brands.”
Colorcon continues to advance technologies and services to meet industry challenges with innovative solutions. This latest technology yet again demonstrates Colorcon’s leadership in responding to the needs of the pharmaceutical industry, bringing novel solutions that are efficient to deliver with dependable performance.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Common stock listed on NASDAQ under the symbol APDN.
Colorcon is a world leader in the development, supply and technical support of specialty ingredients; formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our extensive application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus on market issues and technology development has earned Colorcon an international reputation as a pharmaceutical supplier of choice. That reputation is based on superior product quality, unparalleled technical support, extensive regulatory assistance and reliable supply from multiple locations. Colorcon has 11 manufacturing facilities, 21 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base.
For more information, visit www.colorcon.com.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the possibility of a failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, approval of Applied DNA’s taggant technology by the U.S. Food and Drug Administration or equivalent foreign regulatory agencies as a physical-chemical identifier (PCID) for solid oral dosage forms and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.